Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.

Abstract

In 20 patients with measurable metastatic renal cancer 4'-epi-doxorubicin (Adriamycin) administration (75 mg/m2, every 3 weeks) did not result in any tumor remission. Hematologic and gastrointestinal toxicity was generally mild to moderate. Anthracycline-induced cardiac side effects were not observed in any of the patients.